Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 5, Number 1—February 1999

Perspective

The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals

Robert J. Rubin, Catherine A. Harrington, Anna Poon, Kimberly Dietrich, Jeremy A. Greene, and Adil Moiduddin
Author affiliations: The Lewin Group, Fairfax, Virginia, USA

Main Article

Table 6

Incidence, length of stay, costs, and deaths of Staphylococcus aureus infections by source of infection and degree of resistance

Source of infection Incidence Direct medical cost
Total
($M) Per patient
($) Deaths
Total (%)
Nosocomial 6,300 181.0 28,800 640 10
Community 7,250 254.5 5,300 760 11
Pneumonia 1,500 51.7 34,900 380 25
Non-pneumonia 5,750 202.8 35,400 380 7
MRSAa 2,780 94.5 34,000 590 21
MSSAb 10,770 339.4 31,500 810 8

aMethicillin-resistant strains of S. aureus.
bMethicillin-sensitive strains of S. aureus.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO